44.213.75.78
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-

Trending Topics

No increased risk of cardiorenal outcomes seen after anti-VEGF therapy in eye disease

To determine the risk of developing cardiorenal side effects due to the systemic absorption of intravitreal injections of vascular endothelial growth factor inhibitors (anti-VEGF) therapies, researchers analyzed randomized controlled trials of intravitreal bevacizumab, ranibizumab, and aflibercept for the treatment of any eye disease. Overall, the incidence of hypertension, heart failure,...

Read More
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-